Since aberrant expression of the DUX4 gene has been extensively reported as the main causative factor of FSHD (9–14,20), pre-clinical strategies silencing DUX4 expression have shown promise for FSHD treatment (20,22,24,29,41,51–53). Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.